Jacobson Allan Steven, an insider at PTC Therapeutics Inc (PTCT), purchased 25,351 shares of the company on November 24, 2025, at a price of $18.01 per share, totaling approximately $457,000. Following this transaction, he holds 25,351 shares in the company.
PTC Therapeutics, headquartered in Warren, New Jersey, focuses on developing clinically differentiated medicines for rare disorders. The company has a market capitalization of $6.9 billion and a trailing twelve-month price-to-earnings ratio of 9.21, with earnings per share at 8.53. Its product portfolio includes treatments for Duchenne muscular dystrophy and spinal muscular atrophy, among others.
Insider transactions, such as this purchase, provide transparency into executive confidence in the company’s future. However, these activities should be considered alongside broader market factors and not as standalone indicators of performance. Investors may benefit from analyzing patterns of insider trading over time rather than individual transactions.
PTC Therapeutics is scheduled to report earnings on May 4, 2026, with an estimated EPS of -$0.64 and revenue expectations of $204.8 million, followed by another earnings report on August 5, 2026, with an estimated EPS of -$0.54 and revenue of $222.6 million.